Helicobacter pylori Infection, Chronic Inflammation, and Genomic Transformations in Gastric MALT Lymphoma

Table 2

Chemo/immunotherapy lymphoma as a second line treatment in gastric MALT, phase II trials.

Authors	Treatment	𝑛	CR	PR	SD
Nakamura et al. 2005, [45]	Cyclophosphamide	12	83%		17%
Raderer et al. 2005, [49]	Oxaliplatin	4	56%	38%	6%
Jäger et al. 2006, [50]	Cladribine	19	100%
Martinelli et al. 2005, [51]	Rituximab	27	46%	31%
Conconi et al. 2011, [52]	Bortezomib	13	46%	15%	31%
Zinzani et al. 2004, [46]	Fludarabine and mitoxantrone	20	100%
Raderer et al. 2006, [53]	R-CHOP (15 patients); R-CNOP (11 patients)	26	77%	23%
Troch et al. 2013, [54]	Rituximab and cladribine	40	58%	23%	13%
Kiesewetter et al. 2012, [55]	Lenalidomide	18	33%	27.8%	16.7%

𝑛: number of patients, CR: complete response, PR: partial response, SD: stable disease.
R-CHOP: rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
R-CNOP: rituximab plus cyclophosphamide, mitoxantrone, vincristine, and prednisone.